Abstract
Despite remarkable advances in the treatment and care of breast cancer, therapeutic regimens used to treat this disease still have a significant impact on the health and well-being of patients undergoing treatment. Understanding the potential side effects of these therapies serves the dual purpose of better preparing patients as they enter into treatment and of allowing the medical community to quickly recognize and mitigate the sequelae of treatment. Some of the most common side effects are adverse skin reactions. There are several important groups of therapeutic agents to consider when classifying common cutaneous side effects: conventional chemotherapeutic agents, HER2-targeted therapies, endocrine therapies, and radiation therapy. Here, we discuss the mechanism of action, common side effects, and optimal management methods for each type of therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Allergol Select. 2017;1(1):96–108.
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. 2014;71(2):203.e201–12; quiz 215–206.
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.
Sibaud V, Lebœuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26(5):427–43.
Marchetti MA, Noland MM, Dillon PM, Greer KE. Taxane associated subacute cutaneous lupus erythematosus. Dermatol Online J. 2013;19(8):19259.
Stravodimou A, Voutsadakis IA. Hand and foot syndrome associated with docetaxel treatment. Acta Oncol. 2012;51(4):554–6.
Itoh M, Yanaba K, Kobayashi T, Nakagawa H. Taxane-induced scleroderma. Br J Dermatol. 2007;156(2):363–7.
Lau CP, Hui P, Chan TC. Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. Chin Med J. 2011;124(16):2559–60.
Minisini AM, Tosti A, Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003;14(2):333–7.
Can G, Aydiner A, Cavdar I. Taxane-induced nail changes: predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs. 2012;16(3):270–5.
Huang KL, Lin KY, Huang TW, et al. Prophylactic management for taxane-induced nail toxicity: a systematic review and meta-analysis. Eur J Cancer Care (Engl). 2019;28(5):e13118.
Scotté F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424–9.
Scotté F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112(7):1625–31.
Marks DH, Qureshi A, Friedman A. Evaluation of prevention interventions for taxane-induced dermatologic adverse events: a systematic review. JAMA Dermatol. 2018;154(12):1465–72.
Zawar V, Bondarde S, Pawar M, Sankalecha S. Nail changes due to chemotherapy: a prospective observational study of 129 patients. J Eur Acad Dermatol Venereol. 2019;33(7):1398–404.
Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Investig New Drugs. 1990;8(1):57–63.
Wilkes GM, Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs. 2005;9(1):103–6.
Weger W, Kränke B, Gerger A, Salmhofer W, Aberer E. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol. 2008;59(2 Suppl 1):S4–6.
Chen GY, Chen YH, Hsu MM, Tsao CJ, Chen WC. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol. 2001;145(3):521–2.
Paravar T, Hymes SR. Longitudinal melanonychia induced by capecitabine. Dermatol Online J. 2009;15(10):11.
Muñoz A, Barceló R, Rubio I, Mañé JM, Ferreiro J, López-Vivanco G. Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer. J Natl Cancer Inst. 2003;95(16):1252–3.
Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367–98; quiz 399–400.
Manzione NC, Wolkoff AW, Sassa S. Development of porphyria cutanea tarda after treatment with cyclophosphamide. Gastroenterology. 1988;95(4):1119–22.
Borroni G, Vassallo C, Brazzelli V, et al. Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma. Am J Dermatopathol. 2004;26(3):213–6.
Harrist TJ, Fine JD, Berman RS, Murphy GF, Mihm MC Jr. Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol. 1982;118(4):263–6.
Al-Lamki Z, Pearson P, Jaffe N. Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer. 1996;77(8):1578–81.
Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010:207084.
Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136(12):1475–80.
von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008;44(6):781–90.
Salzberg M, Thurlimann B, Hasler U, et al. Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study. Oncology. 2007;72(3–4):147–51.
Yuan Y, Orlow SJ, Curtin J, Downey A, Muggia F. Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo. Ecancermedicalscience. 2008;2:111.
Sheu J, Hawryluk EB, Litsas G, Thakuria M, LeBoeuf NR. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor. Clin Breast Cancer. 2015;15(1):e77–81.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203–18; quiz 219–220.
Kowalczyk L, Singer CF, Staudigl C, Weber M, Farr A. Adverse mucocutaneous reaction to pertuzumab in a patient with HER2-positive metastatic breast cancer. Breast J. 2017;23(3):352–3.
Alexandrescu DT, Vaillant J, Wiernik PH. Trastuzumab/docetaxel-induced nail dystrophy. Int J Dermatol. 2006;45(11):1334–6.
Andrew P, Valiani S, MacIsaac J, Mithoowani H, Verma S. Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review. Breast Cancer Res Treat. 2014;148(1):1–5.
Cruz MJ, Alves S, Baudrier T, Azevedo F. Porphyria cutanea tarda induced by tamoxifen. Dermatol Online J. 2010;16(9):2.
Praestegaard C, Kjaer SK, Andersson M, Steding-Jensen M, Frederiksen K, Mellemkjaer L. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study. Breast Cancer. 2016;23(6):908–16.
Kim YJ, Cohen PR. Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. Dermatol Ther (Heidelb). 2020;10(1):221–9.
Santoro S, Santini M, Pepe C, et al. Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol. 2011;25(5):596–8.
Yang TJ, Ho AY. Radiation therapy in the management of breast cancer. Surg Clin North Am. 2013;93(2):455–71.
Chan RJ, Larsen E, Chan P. Re-examining the evidence in radiation dermatitis management literature: an overview and a critical appraisal of systematic reviews. Int J Radiat Oncol Biol Phys. 2012;84(3):e357–62.
Kole AJ, Kole L, Moran MS. Acute radiation dermatitis in breast cancer patients: challenges and solutions. Breast Cancer (Dove Med Press). 2017;9:313–23.
Wong RK, Bensadoun RJ, Boers-Doets CB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC skin toxicity study group. Support Care Cancer. 2013;21(10):2933–48.
Roy I, Fortin A, Larochelle M. The impact of skin washing with water and soap during breast irradiation: a randomized study. Radiother Oncol. 2001;58(3):333–9.
Westbury C, Hines F, Hawkes E, Ashley S, Brada M. Advice on hair and scalp care during cranial radiotherapy: a prospective randomized trial. Radiother Oncol. 2000;54(2):109–16.
Campbell IR, Illingworth MH. Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial. Clin Oncol (R Coll Radiol). 1992;4(2):78–82.
Haruna F, Lipsett A, Marignol L. Topical management of acute radiation dermatitis in breast cancer patients: a systematic review and meta-analysis. Anticancer Res. 2017;37(10):5343–53.
Yee C, Wang K, Asthana R, et al. Radiation-induced skin toxicity in breast cancer patients: a systematic review of randomized trials. Clin Breast Cancer. 2018;18(5):e825–40.
Lanigan SW, Joannides T. Pulsed dye laser treatment of telangiectasia after radiotherapy for carcinoma of the breast. Br J Dermatol. 2003;148(1):77–9.
Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer. 2004;111(5):792–4.
Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK. Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast. 2017;35:122–9.
Roychoudhuri R, Evans H, Robinson D, Møller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer. 2004;91(5):868–72.
Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst. 1996;88(24):1848–53.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Floyd, L.P. (2021). Skin Reactions Associated with Breast Cancer Treatment. In: Kimmick, G.G., Shelby, R.A., Sutton, L.M. (eds) Common Issues in Breast Cancer Survivors. Springer, Cham. https://doi.org/10.1007/978-3-030-75377-1_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-75377-1_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-75376-4
Online ISBN: 978-3-030-75377-1
eBook Packages: MedicineMedicine (R0)